ROCHE HOLDINGS AG(RHHVF.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
ROCHE HOLDINGS AG
RHHVF.US
4.961 T
RHHVF.USMarket value -Rank by Market Cap -/-

Financial Score

03/02/2026 Update
B
PharmaceuticalsIndustry
Industry Ranking4/186
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE39.29%A
    • Profit Margin20.33%A
    • Gross Margin74.49%A
  • Growth ScoreB
    • Revenue YoY10.62%B
    • Net Profit YoY69.52%A
    • Total Assets YoY12.85%B
    • Net Assets YoY19.50%A
  • Cash ScoreC
    • Cash Flow Margin491.89%C
    • OCF YoY10.62%B
  • Operating ScoreB
    • Turnover0.63B
  • Debt ScoreD
    • Gearing Ratio62.38%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    FDA Accepts Exelixis Application for Zanzalintinib Combination in Metastatic Colorectal Cancer

    Exelixis Inc. announced that the FDA has accepted its NDA for zanzalintinib in combination with atezolizumab for treating metastatic colorectal cancer in adults who have previously undergone standard chemotherapy. The application is based on the phase 3 STELLAR-303 trial results, which indicated a significant improvement in overall survival compared to regorafenib. The FDA has set a PDUFA target action date of December 3, 2026, with the final analysis of the trial's secondary endpoint expected in mid-2026.

    Reuters·
    US
    BBH
    +0.24%
    US
    BIB
    +2.21%
    US
    ARKG
    +0.62%
    Reuters·
    US
    BBH
    +0.24%
    US
    BIB
    +2.21%
    US
    ARKG
    +0.62%

    Sanegenebio Announces Rnai Global Licensing Collaboration With Genentech

    SANEGENEBIO ANNOUNCES RNAI GLOBAL LICENSING COLLABORATION WITH GENENTECHSANEGENEBIO-WILL RECEIVE UPFRONT PAYMENT OF $200 MILLION, WILL BE ELIGIBLE TO RECEIVE DEVELOPMENT, COMMERCIALIZATION MILESTONE PAYMENTS OF UP TO $1.5 BILLIONSANEGENEBIO - GENENTECH WILL BE RESPONSIBLE FOR SUBSEQUENT CLINICAL DEVELOPMENT AND COMMERCIALIZATION GLOBALLY

    Reuters·
    US
    BBH
    +0.24%
    US
    VHT
    +0.60%
    US
    FBT
    +0.72%
    Reuters·
    US
    BBH
    +0.24%
    US
    VHT
    +0.60%
    US
    FBT
    +0.72%

    Sentinel Trust Co. LBA Buys Shares of 21,507 Roche Holding AG $RHHBY

    Sentinel Trust Co. LBA acquired 21,507 shares of Roche Holding AG (OTCMKTS:RHHBY) valued at approximately $878,000 during Q3, as disclosed to the SEC. Other institutional investors also adjusted their positions in Roche. The company reported strong 2025 results with 7% sales growth and plans to raise dividends. However, currency headwinds impacted earnings, leading to a neutral sentiment among analysts, with Goldman Sachs assigning a "Hold" rating. Roche's stock has a consensus rating of "Moderate Buy" and a price target of $57.00.

    Market Beat·
    US
    BIB
    +2.21%
    US
    IHE
    +1.58%
    US
    RHHVF
    +2.59%
    Market Beat·
    US
    BIB
    +2.21%
    US
    IHE
    +1.58%
    US
    RHHVF
    +2.59%

    Madrigal Pharmaceuticals Gains Patent Control for Rezdiffra in Amended Roche Agreement

    Madrigal Pharmaceuticals Inc. has amended its agreement with F. Hoffmann-La Roche Ltd, granting it full control over patent term adjustments and extensions for Rezdiffra. This includes patents owned or jointly owned by Roche. Additionally, royalty payments to Roche based on Rezdiffra's net sales will remain unchanged until certain patent term extensions expire.

    Reuters·
    US
    VHT
    +0.60%
    US
    XLV
    +0.61%
    US
    ARKG
    +0.62%
    Reuters·
    US
    VHT
    +0.60%
    US
    XLV
    +0.61%
    US
    ARKG
    +0.62%

    Roche Holding AG Reports Earnings Results for the Full Year Ended December 31, 2025

    Roche Holding AG reported earnings results for the full year ended December 31, 2025. For the full year, the company reported sales was CHF 61,516 million compared to CHF 60,495 million a year ago. Revenue was CHF 63,356 million compared to CHF 62,395 million a year ago.Net income was CHF 12,880 million compared to CHF 8,277 million a year ago.

    marketscreener·
    US
    RHHBY
    +0.65%
    US
    RHHVF
    +2.59%
    marketscreener·
    US
    RHHBY
    +0.65%
    US
    RHHVF
    +2.59%
    Posts
    View More

    $Recursion Pharmaceuticals(RXRX.US) Recursion Pharmaceuticals Inc.（RXRX）Weekly Report (2025.11.22-11.29) The extent of your achievements can largely be seen from how much pain you can endure...

    © 2026 Longbridge｜Disclaimer